Clinical Trials
12 trialsNCT02867592 2026-05-27
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06239272 2026-05-19
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT02180867 2026-05-04
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04483778 2026-04-28
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04458922 2026-04-13
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06625190 2026-03-11
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Phase 1/2 Recruiting
NCT03967834 2026-02-10
MIRAS
Institut Claudius Regaud
Phase NA Recruiting
NCT06942442 2025-12-26
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Recruiting
NCT03618381 2025-11-20
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT07153887 2025-09-30
Vebreltinib for Advanced or Metastatic CCS
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting